Literature DB >> 7511075

Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera.

V Ricchiuti1, J P Briand, O Meyer, D A Isenberg, G Pruijn, S Muller.   

Abstract

The reactivity of autoantibodies present in the sera of 489 patients with Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and other autoimmune diseases was investigated by ELISA using recombinant 52-kD SSA/Ro protein (rRo52) and 39 overlapping synthetic peptides representing the entire sequence of Ro52. We report that IgG antibodies reacting with rRo52 were present in the sera of a large number of patients with SS (67% of patients with primary SS and 46% of patients with SS associated with SLE), whereas they were less frequent (10-25%) in SLE, rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and mixed connective tissue disease (MCTD), and absent in scleroderma. Among the 39 peptides tested, five were recognized by sera from 30-65% of patients with SS, namely peptides representing residues 2-11, 107-122, 107-126, 277-292 and 365-382. Patients with JCA had raised levels of IgG antibodies reacting with peptides 2-11 and 365-382, and 51% of patients with MCTD had raised levels of IgG antibodies reacting with peptide 365-382. None of the five peptides was recognized by more than 20% of sera from patients with SLE and RA. Interestingly, and of importance in the field of diagnostic tests based on peptides, the reactivity of antibodies to the Ro52 synthetic peptides varied greatly according to the origin of sera. Inhibition experiments using either patients' sera or antibodies induced in rabbits against Ro52 peptides showed that the four domains 2-11, 107-122, 277-292 and 365-382 are accessible on the surface of the Ro52 protein. These regions may thus be involved in the induction of specific antibodies in autoimmune patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511075      PMCID: PMC1535087          DOI: 10.1111/j.1365-2249.1994.tb07010.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome.

Authors:  E Ben-Chetrit; R I Fox; E M Tan
Journal:  Arthritis Rheum       Date:  1990-03

Review 2.  Structure and function of La and Ro RNPs.

Authors:  W J van Venrooij; R L Slobbe; G J Pruijn
Journal:  Mol Biol Rep       Date:  1993-08       Impact factor: 2.316

3.  Production of antisera with small doses of immunogen: multiple intradermal injections.

Authors:  J L Vaitukaitis
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Autoimmune response to the Ro/SSA particle is directed to the human antigen.

Authors:  M Reichlin; M Rader; J B Harley
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

5.  Human monoclonal anti-La antibodies. The La protein resides on a subset of Ro particles.

Authors:  M J Mamula; E D Silverman; R M Laxer; L Bentur; B Isacovics; J A Hardin
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  Molecular characterization of human Ro/SS-A antigen. Amino terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity of a corresponding synthetic peptide.

Authors:  T S Lieu; M M Newkirk; J D Capra; R D Sontheimer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

7.  An immunohistological study of secondary Sjögren's syndrome.

Authors:  D A Isenberg; D Rowe; A Tookman; A Hopp; M Griffiths; E Paice; J Stewart; P C Beverley
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

8.  mRNA polyadenylate-binding protein: gene isolation and sequencing and identification of a ribonucleoprotein consensus sequence.

Authors:  S A Adam; T Nakagawa; M S Swanson; T K Woodruff; G Dreyfuss
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

9.  HLA-alloantigen associations in Greek patients with Sjögren's syndrome.

Authors:  C A Papasteriades; F N Skopouli; A A Drosos; A P Andonopoulos; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1988-02       Impact factor: 7.094

10.  Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus.

Authors:  J P Buyon; E Ben-Chetrit; S Karp; R A Roubey; L Pompeo; W H Reeves; E M Tan; R Winchester
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

View more
  9 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus.

Authors:  Joanne H Reed; Robert M Clancy; Kristen H Lee; Amit Saxena; Peter M Izmirly; Jill P Buyon
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

4.  Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2).

Authors:  S Cha; P S Leung; J Van de Water; K Tsuneyama; R E Joplin; A A Ansari; Y Nakanuma; P J Schatz; S Cwirla; L E Fabris; J M Neuberger; M E Gershwin; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block.

Authors:  Christine Fritsch; Johan Hoebeke; Hayet Dali; Vincent Ricchiuti; David A Isenberg; Olivier Meyer; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 6.  Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.

Authors:  Edward K L Chan
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-18       Impact factor: 10.817

7.  Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren's syndrome.

Authors:  C S Cho; S H Park; J K Min; S H Lee; H Y Kim
Journal:  Korean J Intern Med       Date:  1997-06       Impact factor: 2.884

8.  Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis.

Authors:  Athanasios Gkoutzourelas; Christos Liaskos; Maria G Mytilinaiou; Theodora Simopoulou; Christina Katsiari; Alexandra Tsirogianni; Dimitrios Daoussis; Thomas Scheper; Wolfgang Meyer; Dimitrios P Bogdanos; Lazaros I Sakkas
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

9.  Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.

Authors:  Jennifer C Parker; Rufus W Burlingame; Christopher C Bunn
Journal:  J Autoimmune Dis       Date:  2009-03-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.